Feraheme Recall Issued In Switzerland After Hypersensitivity Deaths

A batch of anemia, drugs known as Ferahame, have been recalled in Switzerland following the death of at least one patient and several reports involving hypersensitivity reactions.  

Known in Switzerland as Rienso, makers Amag Pharmaceuticals and Takeda Pharmaceuticals issued a Feraheme recall earlier this week. The recall is limited to Switzerland, but the same medication is sold in the U.S. and other countries as well.

The recall came after reports of hypersensitivity reactions with Feraheme in Switzerland, which the makers believe may be tied to a specific batch sold there. They are investigating the batch and adverse event reports from Switzerland and other countries to see if the problem is more widespread.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Four Swiss patients suffered hypersensitivity reactions after taking the drug and one died. All appear to be linked to the same batch. New batches of the drug will not be sent to the Swiss without approval from that government.

Feraheme (ferumoxyo) is approved to treat anemia in patients with chronic kidney disease. It belongs to a class of drugs known as parental iron replacement drugs. The drug carries warnings of possible hypersensitivity and anaphylactic reactions that could be fatal.

Other anemia treatments, such as the erythropoiesis-stimulating agents (ESAs) Aranesp, Epogen and Procrit have also come under fire in recent years amid concerns about potential health risks.

Aranesp (darbepoetin alfa), Epogen (Epoetin alfa) and Procrit (Epoetin alfa) are ESAs prescribed to patients with kidney disease, anemia, HIV and cancer to stimulate bones to increase the production of red blood cells. They are also prescribed to patients preparing to undergo major non-heart surgery to reduce the number of transfusions such patients must receive. Amgen manufactures all three drugs, though Procrit is sold and marketed by Johnson and Johnson.

The FDA issued a public health advisory regarding the drugs in 2007, saying that the Anemia drugs could increase the risk of injury or death at high doses. The FDA required the black box warning to alerting patients to the cardiovascular health risks. The black box warning is the strongest label warning the FDA can require of a medication.

The drugs are already restricted under an FDA-required risk evaluation and mitigation strategy (REMS). Doctors and hospitals that wish to prescribe the drugs will now have to undergo special training to identify high risk users and negative side effects.

Image Credit: |


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks
Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks (Posted today)

Women who used Johnson's Baby Powder around their genitals for feminine hygiene purposes now live in fear of developing ovarian cancer, according to the class action lawsuit seeking medical monitoring for future diagnoses

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted yesterday)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.